First-line treatment for patients with CML in chronic phase: Second-generation TKIs are the therapy of choice

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
JournalONCOLOGY (United States)
Volume27
Issue number8
StatePublished - Jan 1 2013
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this